Mar 15, 2023 / 01:15PM GMT
Charles Zhu - Guggenheim Partners - Analyst
(technical difficulty) and thanks for joining us today. I'm Charles Zhu. I'm one of the senior biotech analysts here at Guggenheim. With me here today is Yujiro Hata, CEO of IDEAYA Biosciences. Thank you for joining us here today as well. Perhaps just to kick us off very quickly, a one-minute overview of your company pipeline and platform.
Yujiro Hata - IDEAYA Biosciences, Inc. - President & CEO
First, Charles, thanks so much to Guggenheim to inviting us again to the event this year. So quickly, the company was founded just over 7.5 years ago with a core focus to build the leading synthetic lethality focused-precision medicine oncology company.
Today, we have three first-in-class clinical programs, darovasertib, which we're targeting to have a discussion with the FDA this month on a potential registration-enabling trial. The second program, which is a MAT2A inhibitor, here, the patient selection biomarker is MTAP deletion, that's believed to represent roughly 15% of all solid tumors. Here, the key focus is
IDEAYA Biosciences Inc at Guggenheim Healthy Altitudes Summit Transcript
Mar 15, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers